ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
Recruiting
- Conditions
- Invasive Aspergillosis
- Registration Number
- NCT06028451
- Lead Sponsor
- Southeast University, China
- Brief Summary
To assessed the current situation and outcome of critically ill patients with invasive aspergillus infection.
- Detailed Description
To assessed the current situation and outcome of critically ill patients with invasive aspergillus infection.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 550
Inclusion Criteria
- Age>18 year-old
- Diagosed as invasive aspergillus infection
Exclusion Criteria
- Pregnant
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method mortality 28 day
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antifungal resistance in invasive aspergillosis patients enrolled in NCT06028451?
How does the real-world effectiveness of antifungal drugs in NCT06028451 compare to standard-of-care regimens for invasive aspergillosis?
Which biomarkers are associated with improved outcomes in critically ill invasive aspergillosis patients receiving antifungal therapy in NCT06028451?
What adverse events are reported in NCT06028451 for antifungal drug management of invasive aspergillosis, and how are they managed?
Are there combination therapies or alternative antifungal agents being explored alongside the observational strategies in NCT06028451 for invasive aspergillosis?
Trial Locations
- Locations (1)
Southeast University, Zhongda hospital
🇨🇳Nanjing, Jiangsu, China
Southeast University, Zhongda hospital🇨🇳Nanjing, Jiangsu, ChinaJingyuan Xu, M.D.Principal Investigator